CJC-1295 No DAC & Ipamorelin: Research Flexibility Considerations

For a wholesale buyer, the flexibility question around CJC-1295 no DAC and ipamorelin resolves into three practical points. The two compounds act on separate, well-documented receptor pathways, so the research literature treats them as distinct subjects rather than interchangeable ones. The no-DAC designation refers to the absence of a Drug Affinity Complex, and published characterizations describe that unmodified form as short-acting rather than long-circulating. And commercially, both are stocked as standalone research vials — not a pre-combined blend — which means a buyer can adjust each line independently and verify purity on each compound's own certificate of analysis. Real Peptides supplies both as research-use-only compounds through its Wholesale Partner Program. Nothing on this page is dosing, preparation, or administration guidance, and none of these compounds are approved drugs.

What the "no DAC" suffix actually designates

CJC-1295 exists in the research supply chain in two structurally different forms, and the label suffix is the only thing distinguishing them on a packing slip. The DAC-modified version carries a Drug Affinity Complex — a chemical moiety described in the literature as binding to serum albumin, which published work associates with a markedly extended plasma presence. The no-DAC form omits that moiety entirely. It is a modified analog of growth-hormone-releasing factor, and characterizations in the research literature describe it as short-acting.

Why does that matter to someone stocking a catalog rather than running an assay? Because the two forms are not substitutes, and buyers searching for one will not accept the other. A supplier who lists "CJC-1295" without specifying the form is either careless with labeling or hoping the distinction goes unnoticed — and both possibilities should push you toward a supplier whose product pages and COAs name the exact compound. The catalog listing for CJC-1295 No DAC 10mg is specific by design, because the identity of what's in the vial is the first thing a research buyer checks.

The short-acting profile is also the source of the word "flexibility" in the research context. Studies investigating pulsatile signaling generally require a compound whose plasma presence can be bounded within a study window; a long-circulating analog changes what a given experimental design can isolate. That is a statement about study design in research models, not about use in people.

Two receptor pathways, two separate bodies of research

Ipamorelin is a pentapeptide, and research describes it as an agonist at the growth hormone secretagogue receptor — the ghrelin receptor pathway. CJC-1295 no DAC works through the GHRH receptor pathway. These are genuinely different mechanisms, and preclinical literature has examined each on its own terms as well as in combination in animal and cell models.

This pathway separation is the second reason the pairing appears so often in search queries. Research suggests the two receptor systems interact rather than duplicate each other, which is why investigators studying growth hormone axis signaling frequently reference both compounds in the same paper. Studies report that ipamorelin shows selectivity relative to older secretagogues in preclinical work — a finding that made it a common comparison compound in the literature.

What this does not mean: it does not mean the two compounds should be combined, prepared together, or used in any protocol. Real Peptides does not publish protocols. The commercial takeaway is narrower and more useful — research demand for these two compounds tends to move together, so a buyer stocking one should expect inquiries about the other, and should plan catalog depth accordingly. Both sit within the broader growth factor and tissue signaling research category, alongside compounds like Tesamorelin 10mg, which research also characterizes as a GHRH analog.

Side-by-side: what separates the two catalog items

The last row carries more weight than it looks like it should. A pre-blended vial gives you one certificate covering one fixed ratio. Two separate vials give you two certificates, two independently testable identities, and two SKUs you can reorder on different cycles as demand shifts.

Flexibility as an inventory decision

Strip out the chemistry and "flexibility" becomes a stocking problem. Separate SKUs let you carry different depths of each compound instead of guessing at a ratio in advance. If inquiries for one line outpace the other in a given quarter, you reorder that line — you are not sitting on blended stock that satisfies neither pattern of demand.

Separate SKUs also preserve your audit trail. When a customer asks what's in the vial, you hand over the COA for that lot of that compound. With a blend, you are explaining a composite, and any purity question about one component becomes a question about the whole vial. For resellers building a brand, that traceability is often worth more than the small convenience of a combined item.

The third practical point is shelf life and handling. Lyophilized research peptides have their own storage requirements, and two compounds stored separately in their original state give you cleaner handling documentation than a combined preparation would. Concentration math — total labeled mass relative to volume of solvent, expressed as mg per mL — is the outer boundary of what any responsible supplier discusses, and it is the boundary Real Peptides holds. Anything past that line is the buyer's laboratory decision, not a supplier's to script.

What to verify before buying either compound from anyone

These two compounds are widely listed, which means the differences between suppliers show up in documentation rather than in the product name. Five things are worth verifying before you place a first order with any wholesale source.

Purity, stated with a method. A purity claim means little without the analytical method behind it. Ask whether the figure comes from HPLC analysis and whether it applies to the specific lot you're receiving.

COA access, without a paywall. Some operations treat certificates of analysis as a paid extra or send them only on request after purchase. A COA you can pull up and read before you commit is a materially different proposition from one you have to ask for. Real Peptides publishes verifiable COAs so a prospective partner can check the lab results independently.

Panel scope. Identity and purity are the headline figures, but they aren't the whole picture. Real Peptides runs 7-panel batch testing, which covers more than a single purity readout. When a supplier says "tested," ask what was tested for.

Pricing transparency. Hidden tier pricing — where you cannot see what volume moves you to a better rate until you've already committed — makes planning difficult. Margins and landed cost vary widely with volume, compound category, and freight, so no honest supplier can quote you a universal number. What a supplier can do is show you the structure before you apply.

Fulfillment reality. Ask where orders ship from and what the actual cycle looks like. Real Peptides fulfills from within the United States in five to seven days, which is a different planning horizon from overseas transshipment.

The regulatory questions that belong with your counsel

This section is informational and is not legal advice. Research-use-only compounds sit in a regulatory area where the answers depend on your business model, your professional licensure, and your state — so the useful thing is knowing which questions to bring to your attorney and your state board rather than reading a conclusion online.

Ask how your entity type and license, if you hold one, affect what you may purchase, store, and resell. Ask what your state board's position is on research-use-only materials in a commercial setting, and get that answer from the board or from counsel rather than from a supplier. Ask what labeling, record-keeping, and documentation obligations attach to your specific operation. Ask how your professional liability coverage treats research compounds. And ask what representations you may and may not make to your own customers — that question is often the most consequential and the most frequently skipped.

Any supplier telling you a given state permits or forbids something, flatly and without qualification, is overstepping. Real Peptides supplies compounds for research use and documents them thoroughly; your compliance posture is yours to establish with your own counsel.

What Real Peptides does differently

The program is built around documentation a partner can check rather than claims a partner has to accept. Every compound in the catalog is produced to 99%+ HPLC purity. Every batch goes through 7-panel testing, and the resulting certificates of analysis are publicly verifiable — a prospective partner can look at the lab results before applying, not after. Orders fulfill from the United States in five to seven days, which keeps reorder planning on a predictable cycle rather than an import schedule.

The Wholesale Partner Program application is three steps, and pricing tiers are shown to approved partners as a structure rather than discovered order by order. Both CJC-1295 No DAC and Ipamorelin 10mg are stocked as independent SKUs with their own batch documentation — no blends, no composite certificates. And the program does not offer semaglutide, tirzepatide, retatrutide, or Melanotan II; the catalog is what the catalog says it is.

If you're a med spa operator, clinic, telehealth company, or reseller building a research peptide line and the documentation standard above matches what you need to stand behind, the Wholesale Partner Program application is the next step — three steps, and pricing tiers become visible once you're approved.

For related reading, the Popular Peptides collection covers the compounds wholesale buyers ask about most often, Performance & Recovery Research groups compounds such as BPC-157 10mg and TB-500 10mg, and the Mitochondrial & Metabolic Pathway Research category includes items like MOTS-c 10mg.